Loading
companiesCompany
Sinocelltech
Sinocelltech is a China-based biotechnology company running 8 late-stage cancer trials of SCTB41, SCTB35 and SCTC21C in multiple myeloma, non-small-cell lung cancer and diffuse large B-cell lymphoma.
Also called: Sinocelltech Ltd.
Overview
Sinocelltech, based in Beijing, China, is a biotechnology company. Sinocelltech is a biopharmaceutical company that researches, manufactures and commercialises monoclonal antibodies, recombinant proteins and vaccines. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (6 in phase 3), testing SCTB41, SCTB35, SCTC21C, SCTB39-1 and SCTB14 in multiple myeloma, non-small-cell lung cancer, diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT06041061 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years), plans to enrol 18000 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Beijing, CN
Scorecard
All companies#235of 1244 companies, score 22
- phase 3 +12
- modalities +2
- registry trials +8
0 approved, 4 in phase 3, 0 earlier, 0 targets, 16 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2002
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
SCTB41 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
SCTB35 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
SCTC21C is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
SCTB14 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
cancers
drugs
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
trials
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II StudyA Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 YearsA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantA Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung CancerAims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.Phase I/II Study of SCTB39-1 in Advanced Solid TumoursSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer